Related Experiment Video

Updated: Jun 6, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Β-arrestin: a signaling molecule and potential therapeutic target for heart failure

Nabila Noor1, Chetan B Patel, Howard A Rockman

  • 1Duke University School of Medicine, Durham, NC, USA.

Journal of Molecular and Cellular Cardiology
|November 16, 2010
PubMed

Insights

Beta-arrestin, a protein involved in G-protein coupled receptor signaling, offers a novel therapeutic target for heart failure. It mediates protective signaling pathways independent of traditional G-protein actions.

Area of Science:

  • Cardiology
  • Molecular Pharmacology
  • Biochemistry

Background:

  • Current heart failure treatments target G-protein coupled receptors (GPCRs) like beta-adrenergic receptors (β1AR, β2AR) and angiotensin II type IA receptors (AT1aR).
  • GPCR ligands can block detrimental G-protein pathways and activate G-protein independent pathways involving beta-arrestin.
  • Beta-arrestin, initially linked to GPCR desensitization, now shows protective roles in cardiac signaling.

Purpose of the Study:

  • To review the multifaceted signaling roles of beta-arrestin in the context of heart failure.
  • To explore the potential of beta-arrestin as a therapeutic target for novel heart failure treatments.
  • To highlight the dual signaling capacity of beta-arrestin in inhibiting deleterious pathways and activating beneficial ones.

Main Methods:

  • Literature review of G-protein coupled receptor signaling pathways.
  • Analysis of beta-arrestin's role in both G-protein dependent and independent signaling.
  • Exploration of therapeutic strategies targeting beta-arrestin in cardiac disease.

Main Results:

  • Beta-arrestin mediates G-protein independent signaling that can be protective to the heart.
  • The multifunctional nature of beta-arrestin presents opportunities for developing next-generation cardiac drugs.
  • Targeting beta-arrestin may allow simultaneous inhibition of harmful G-protein pathways and activation of beneficial beta-arrestin pathways.

Conclusions:

  • Beta-arrestin is a key signaling molecule with significant potential in treating heart failure.
  • Future drug development for cardiac diseases could leverage beta-arrestin's unique signaling capabilities.
  • Understanding beta-arrestin signaling is crucial for advancing cardiovascular medicine.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...